Abstract 2360
Background
Extranodal marginal zone lymphoma is a type of low-grade B-cell lymphoma and may be classified as mucosal-associated lymphoid tissue (MALT) lymphoma. MALT lymphoma is most common in stomach in Korea. The etiologic factors are inflammation caused by chronic infection, autoimmune disease and genetic variation. Identifying various somatic mutations is an essential process in precision medicine, where high throughput sequencing is used to accurately detect genetic changes. Nucleotide sequencing techniques are basically based on the Sanger method, but recently second generation or next generation sequencing (NGS) that can sequence millions or billions of DNA strands simultaneously in parallel unlike the sanger sequencing is rapidly spreading.
Methods
One gastric MALT lymphoma and four small intestine MLAT lymphomas were selected and studied using tissue samples embedded in their paraffin. DNA was extracted from tissue samples and quality control was performed. NGS was performed using HemaSCANTM, a custom panel for 426 genes including essential genes for blood cancer.
Results
The results of NGS revealed the following genomic variants; single nucleotide variations (SNVs), insertions and deletions (InDels) and copy number variations (CNVs). And these genomic variants are reported as annotated, known, and novel variants. Of the annotated variant, ERBB2 gene amplification was confirmed in one patient. Of the known and novel variants, SNV of SETBP6, RUNX1 and KEAP1 gene, InDel of MKI67 gene, CNV of ZNF703 and NOTCH1 gene were confirmed in two or more patients. And InDel with frameshift in BCL10, DDX3X, FOXO3 and MUC2 genes was identified in one patient.
Conclusions
Since there are few NGS studies on MALT lymphoma, the various mutations identified in this study cannot be said to be “inactionable”. More studies are needed to determine the association of various genetic mutations with the development of MALT lymphoma.
Clinical trial identification
Editorial acknowledgement
Seok Jae Huh1, Sung Yong Oh1, Suee Lee1, Ji Hyun Lee1, Sung Hyun Kim1, Min Kyung Park2, and Hyo-Jin Kim1 1Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea, 2Department of Pathology, Dong-A University College of Medicine, Busan, Republic of Korea.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract